UNSPSC 51161717: Fenspiride

This classification denotes a vasodilating agent with the molecular formula C15H20N2O2, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier S983QC7HKM, chemically known as 1-oxa-3,8-diazaspiro(4.5)decan-2-one, 8-phenethyl- but generally known as fenspiride, which bears US NIH Compound Identifier 3344. European Medicines Agency schedules Fenspiride in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB07596MIG.

UNSPSC 51161717 Fenspiride is a Commodity code with minimal recent state and local solicitation activity directly aligned to this specific pharmaceutical ingredient. The recent opportunities tagged to this code span a broader pharmaceutical and pharmacy services procurement landscape: naloxone and drug deactivation systems, on-site pharmacy services for county employee health plans, direct-to-manufacturer prescription programs at the state level, and generic multi-source pharmaceuticals through cooperative purchasing. The actual work being procured under this code designation includes emergency medical supplies (naloxone), comprehensive pharmacy benefit administration for municipal employees, and bulk generic pharmaceutical distribution through state and local cooperative purchasing vehicles. The issuing bodies range from county health departments and county government benefits administrators to state health and human services commissions and multistate cooperative purchasing alliances, indicating fragmented demand across different municipal and state procurement tiers rather than concentrated buying by a single jurisdiction type.

Recent activity appears across three states. Seminole County, Florida posted an IFB (IFB60459723LAS) on June 30, 2026, for 1,900 units of naloxone and 800 safe drug deactivation systems annually with quarterly deliveries due July 26, 2026, through electronic bidding. Hall County, Georgia issued an RFQ/P (#47-010) on May 4, 2026, for on-site pharmacy services at its Family Health Center Clinic serving approximately 3,005 eligible individuals, with sealed proposals due June 4, 2026, using an 80/20 technical-to-cost scoring model and a one-year initial term beginning January 1, 2027. The Texas Health and Human Services Commission posted a Request for Information (RFI HHS0017013) on April 3, 2026, seeking vendor capabilities for direct-to-manufacturer prescription programs outside traditional pharmacy benefit manager arrangements. The Minnesota Multistate Cooperative Purchasing Alliance (MMCAP) issued an RFP for generic multi-source pharmaceuticals and OTC products with a March 26, 2026, response deadline, requiring supply through three authorized wholesalers and effective July 1, 2026. The code shows scattered recent activity rather than sustained demand concentration, suggesting limited relevance for vendors focused specifically on fenspiride ingredient supply.